


IN THE CLAIMS

1. (currently amended) A compound of formula 1



wherein

$R^1$

(i) is  $-C_{1-10}$ -alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by ~~OH, SH,  $NH_2$ ,  $NHC_{1-6}$ -alkyl,  $N(C_{1-6}$ -alkyl) $_2$ ,  $NHC_{6-14}$ -aryl,  $N(C_{6-14}$ -aryl) $_2$ ,  $N(C_{1-6}$ -alkyl)( $C_{6-14}$ -aryl),  $NO_2$ , CN, F, Cl, Br, I,  $O-C_{1-6}$ -alkyl,  $O-C_{6-14}$ -aryl,  $S-C_{1-6}$ -alkyl,  $S-C_{6-14}$ -aryl,  $SO_2H$ ,  $SO_2C_{1-6}$ -alkyl,  $SO_2C_{6-14}$ -aryl,  $OSO_2C_{1-6}$ -alkyl,  $OSO_2C_{6-14}$ -aryl,  $COOH$ ,  $(CO)C_{1-5}$ -alkyl,  $COO-C_{1-5}$ -alkyl,  $O(CO)C_{1-5}$ -alkyl,~~ by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members ~~or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms,~~ which are preferably N, O and S,

wherein the  ~~$C_{6-14}$ -aryl groups~~ and the carbocyclic and heterocyclic substituents in turn are substituted one or more times by  $-NO_2$  and may optionally be substituted one or more times by  $-C_{1-6}$ -alkyl,  $-OH$ ,  $-NH_2$ ,  $-NHC_{1-6}$ -alkyl,  $-N(C_{1-6}$ -alkyl) $_2$ ,  $-NO_2$ ,  $-CN$ ,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O-C_{1-6}$ -alkyl,  $-$

25543188.1

S-C<sub>1-6</sub>-alkyl, -SO<sub>3</sub>H, -SO<sub>2</sub>C<sub>1-6</sub>-alkyl, -OSO<sub>2</sub>C<sub>1-6</sub>-alkyl, -COOH, -(CO)C<sub>1-5</sub>-alkyl, -COO-C<sub>1-5</sub>-alkyl or/and -O(CO)C<sub>1-5</sub>-alkyl, and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by -OH, -SH, -NH<sub>2</sub>, -F, -Cl, -Br, -I, -SO<sub>3</sub>H or/and -COOH, or

(ii) is ~~C<sub>2-10</sub>-alkenyl, mono or polyunsaturated, straight chain or branched chain, optionally mono or polysubstituted by -OH, -SH, -NH<sub>2</sub>, -NHC<sub>1-6</sub>-alkyl, N(C<sub>1-6</sub>-alkyl)<sub>2</sub>, NHC<sub>6-14</sub>-aryl, N(C<sub>6-14</sub>-aryl)<sub>2</sub>, N(C<sub>1-6</sub>-alkyl)(C<sub>6-14</sub>-aryl), -NO<sub>2</sub>, -CN, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub>-alkyl, -O-C<sub>6-14</sub>-aryl, -S-C<sub>1-6</sub>-alkyl, -S-C<sub>6-14</sub>-aryl, -SO<sub>3</sub>H, -SO<sub>2</sub>C<sub>1-6</sub>-alkyl, -SO<sub>2</sub>C<sub>6-14</sub>-aryl, -OSO<sub>2</sub>C<sub>1-6</sub>-alkyl, -OSO<sub>2</sub>C<sub>6-14</sub>-aryl, -COOH, -(CO)C<sub>1-5</sub>-alkyl, -COO-C<sub>1-5</sub>-alkyl, -O(CO)C<sub>1-5</sub>-alkyl, by mono-, bi- or tricyclic saturated or mono or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,~~

wherein the C<sub>6-14</sub>-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by ~~C<sub>1-6</sub>-alkyl, -OH, -NH<sub>2</sub>, -NHC<sub>1-6</sub>-alkyl, -N(C<sub>1-6</sub>-alkyl)<sub>2</sub>, -NO<sub>2</sub>, -CN, -F, -Cl, -Br, -I, -O-C<sub>1-6</sub>-alkyl, -S-C<sub>1-6</sub>-alkyl, -SO<sub>3</sub>H, -SO<sub>2</sub>C<sub>1-6</sub>-alkyl, -OSO<sub>2</sub>C<sub>1-6</sub>-alkyl, -COOH, -(CO)C<sub>1-5</sub>-alkyl, -COO-C<sub>1-5</sub>-alkyl or/and -O(CO)C<sub>1-5</sub>-alkyl,~~

and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by ~~-OH, -SH, -NH<sub>2</sub>, -F, -Cl, -Br, -I, -SO<sub>3</sub>H or/and -COOH,~~

R<sup>2</sup> is hydrogen or -C<sub>1-3</sub>-alkyl,

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> ~~R<sup>4</sup> and R<sup>5</sup>~~ are hydrogen or a hydroxyl group, wherein at least one of these substituents must be a hydroxyl group,

$R^6$  and  $R^7$  may be identical or different and are hydrogen,  $-C_{1-6}$ -alkyl,  $-OH$ ,  $-SH$ ,  $-NH_2$ ,  $-NHC_{1-6}$ -alkyl,  $-N(C_{1-6}$ -alkyl) $_2$ ,  $-NO_2$ ,  $-CN$ ,  $-SO_3H$ ,  $-SO_3-C_{1-6}$ -alkyl,  $-COOH$ ,  $-COO-C_{1-6}$ -alkyl,  $-O(CO)-C_{1-5}$ -alkyl,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O-C_{1-6}$ -alkyl,  $-S-C_{1-6}$ -alkyl,  $-phenyl$  or  $-pyridyl$ , wherein the phenyl or pyridyl substituents in turn may optionally be substituted one or more times by  $-C_{1-3}$ -alkyl,  $-OH$ ,  $-SH$ ,  $-NH_2$ ,  $-NHC_{1-3}$ -alkyl,  $-N(C_{1-3}$ -alkyl) $_2$ ,  $-NO_2$ ,  $-CN$ ,  $-SO_3H$ ,  $-SO_3C_{1-3}$ -alkyl,  $-COOH$ ,  $-COOC_{1-3}$ -alkyl,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-O-C_{1-3}$ -alkyl,  $-S-C_{1-3}$ -alkyl, or/and  $-O(CO)C_{1-3}$ -alkyl, and wherein the alkyl substituents in turn may optionally be substituted one or more times by  $-OH$ ,  $-SH$ ,  $-NH_2$ ,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-SO_3H$ ,  $-SO_3C_{1-3}$ -alkyl,  $-COOH$ ,  $-COOC_{1-3}$ -alkyl,  $-O-C_{1-3}$ -alkyl,  $-S-C_{1-3}$ -alkyl or/and  $-O(CO)-C_{1-3}$ -alkyl,

or salts of the compounds of formula 1.

2. (previously presented) A compound as claimed in claim 1 having at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (previously presented) A compound as claimed in claim 1 wherein  $R^2$  is hydrogen or a methyl group.

4. (previously presented) A compound as claimed in claim 1, wherein  $R^3 = -H$ ,  $R^4 = H$  and  $R^5 = -OH$ .

5. (previously presented) A compound as claimed in claim 1, wherein at least one of  $R^6$  and  $R^7$  is a halogen atom.

6. (currently amended) A compound according to claim 1 selected from the group consisting of:

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

25543188.1

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-4-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(3-nitrobenzyl)-indol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(2-nitrobenzyl)-indol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-isobutylindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(1-cyclopropyl-methyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(4-hydroxybenzyl)-indol-3-yl]glyoxylamide;~~

25543188.1

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~


~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;~~

and physiologically tolerated salts thereof.

7. (canceled)

8. (currently amended) A process for comprising preparing a compound of claim 1 by 1, comprising converting N-(pyridine-4-yl)-indol-3-ylglyoxylamides of formula 2



into the analogous N-(1-oxopyridin-4-yl)-indol-3-ylglyoxylamides of formula 1 by treatment with an oxidizing agent, and forming the compound by eliminating a protective group.

9. (currently amended) ~~The~~ A process as claimed in claim 8, said oxidizing agent is selected from the group consisting of a peracid and a peracetic acid.

10. (currently amended) A method of treating disorders in which inhibition of phosphodiesterase 4 is therapeutically beneficial comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to ~~of~~ claim 1 to treat the disorder.

11. (currently amended) A method of treating disorders associated with the effect of eosinophils comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the disorder.

12. (currently amended) A method of treating disorders associated with the effect of neutrophils comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the disorder.

13. (currently amended) A method of treating a hyperproliferative disorder comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the hyperproliferative disorder.

14. (currently amended) A drug product comprising a compound of claim 1 and a at least one conventional physiologically tolerated carrier, diluent and excipient.

15. (currently amended) A process for producing a drug product comprising admixing a compound of claim 1 with a at least one conventional pharmaceutical carrier, diluent or excipient to form the drug product.

16. (currently amended) A pharmaceutical composition comprising a at least one compound according to claim 1 and at least one additional active pharmaceutical agent.

17. (previously presented) The process as claimed in claim 8, wherein said oxidizing agent is m-chloroperbenzoic acid.